A perspective on B-cell-targeting therapy for SLE

References

• Martin F, Chan AC. Pathogenic roles of B cells in human auto-immunity; insights from the clinic. Immunity. 2004;20(5):517–27.
   PubMed Web of Science ®Google Scholar
• Sobel E, Katagiri T, Katagiri K, Morris S, Cohen P, Eisenberg R. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmu-nity. J Exp Med. 1991;173:1441–9.
   PubMed Web of Science ®Google Scholar
• Silverman G, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003;48:1484–92.
   PubMed Web of Science ®Google Scholar
• Silverman GJ. Anti-CD20 therapy in systemic lupus erythema-tosus: a step closer to the clinic (comment) (erratum appears in Arthritis Rheum. 2005 Apr; 52(4):1342). Arthritis Rheum 2005;52(2):371–7.
   Google Scholar
• Shlomchik MC, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1:147–53.
   Google Scholar
• Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580–9.
   PubMed Web of Science ®Google Scholar
• Lu TYT, Ng KP, Cambridge G, Leandro MJ, Edwards JCW, Ehrenstein M, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009;61(4):482–7.
   PubMed Web of Science ®Google Scholar
• Saito K, Nawata M, Nakayamada S, Tokunaga M, Tsukada J, Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involve-ment. Lupus. 2003;12(10):798–800.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, Sundelin B, Osterborg A, Jacobson SH, et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol. 2004;33(6):423–7.
   Google Scholar
• Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis fol-lowing B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial (see comment). Arthritis Rheum. 2005;52(2):501–13.
   PubMedGoogle Scholar
• Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus (see comment). N Eng J Med. 2003;349(16):1526–33.
   PubMed Web of Science ®Google Scholar
• Cassese G, Lindenau S, de Boer B, Arce S, Hauser A, Riemekasten G, et al. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol. 2001;31(9):2726–32.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum. 1982;25(4):401–6.
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in sys-temic lupus erythematosus. Science. 2001;294(5546):1540–3.
   Google Scholar
• Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SUE) have a circu-lating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol. 1999;115(1):196–202.
   Google Scholar
• Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SUE. Trends Immunol. 2001;22(8):427–31.
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Alm GV. The natural interferon-alpha producing cells in systemic lupus erythematosus. Hum Immunol. 2002; 63(12):1181–93.
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther. 2003;5(2):68–75.
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Pascual V. The innate immune system in SUE: type I interferons and dendritic cells. Lupus. 2008;17(5):394–9.
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors (see comment). Nature. 2002;416(6881):603–7.
   Google Scholar
• Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like recep-tors. Semin Immunol. 2007;19(1):11–23.
   PubMed Web of Science ®Google Scholar
• Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus (see comment). Immunity. 2006;25(3):417–28.
   PubMed Web of Science ®Google Scholar
• Herlands RA, Christensen SR, Sweet RA, Hershberg U, Shlomchik MJ. T cell-independent and toll-like receptor-depen-dent antigen-driven activation of autoreactive B cells. Immunity. 2008;29(2):249–60.
   Google Scholar
• Sanz I, Wei C, Lee FE-H, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008;20(1):67–82.
   Google Scholar
• Manjarrez-Orduno N, Quach TD, Sanz I. B cells and immuno-logical tolerance. J Investig Dermatol. 2009;129(2):278–88.
   Google Scholar
• Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol. 1998;160(1):51–9.
   PubMed Web of Science ®Google Scholar
• Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999;189(10):1639–48.
   Google Scholar
• Chan OT, Madaio MP, ShlomchikMJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev. 1999;169:107–21.
   Google Scholar
• Matsushita T, Yanaba K, Bouaziz J-D, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression (see comment). J Clin Investig. 2008;118(10):3420–30.
   Google Scholar
• Lampropoulou V, Hoehlig K, Roch T, Neves P, Calderon Gomez E, Sweenie CH, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol. 2008;180(7):4763–73.
   PubMed Web of Science ®Google Scholar
• Kurosaki T. Paradox of B cell-targeted therapies (comment). J Clin Investig. 2008;118(10):3260–3.
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol. 2008;8:391–7.
   Google Scholar
• Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol. 2007;178(12):7868–78.
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002;16(2):219–30.
   Google Scholar
• Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28(5):639–50.
   Google Scholar
• Clatworthy MR, Watson CJE, Plotnek G, Bardsley V, Chaudhry AN, Bradley JA, et al. B-cell-depleting induction therapy and acute cellular rejection. N Eng J Med. 2009;360(25):2683–5.
   PubMed Web of Science ®Google Scholar
• Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis (see comment). N Eng J Med. 2004;350(25):2572–81.
   Google Scholar
• Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting mul-tiple sclerosis (see comment). N Eng J Med. 2008;358(7):676–88.
   PubMed Web of Science ®Google Scholar
• Merrill J, Neuwelt C, Wallace D, Shanahan J, Latinis K, Oates J, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the Randomized, Double-blind Phase II/III Study EXPLORER American College of Rheumatology National Meeting 2008; Abstract L12.
   Google Scholar
• Ng K, Mason J, Rahman A, Isenberg D. Association of antinu-cleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Care Res. 2006;55:900–4.
   Web of Science ®Google Scholar
• Anolik J, Looney R, Lund F, Randall T, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009; (EPub ahead of print April 7).
   Google Scholar
• Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109.
   PubMed Web of Science ®Google Scholar
• Chatham W, Furie R, Petri M, Ginzler E, Wallace D, Stohl W, et al. Belimumab (fully human monoclonal antibody to BLyS) improved or stabilized systemic lupus erythematosus (SLE) dis-ease activity over 3 years of therapy American College of Rheumatology National Meeting 2008; Abstract 1094.
   Google Scholar
• Petri M. Novel Combined Response endpoint and systemic lupus erythematosus (SLE) flare index (SFI) demonstrate belimumab (fully human monoclonal antibody to BLyS) improves or stabi-lizes SLE disease Activity and reduces flare rate over 2.5 years of Therapy American College of Rheumatology National Meeting 2007; Abstract 1316.
   Google Scholar
• Furie R, Lisse J, Merrill J, Petri M, Ginzler E, Aranow C, et al. Belimumab (fully human monoclonal antibody to B-Lymphocyte stimulator [BLyS]) improves or stabilizes SLE activity in a multicenter phase 2 trial. American College of Rheumatology National Meeting 2006; Abstract 535.
   Google Scholar
• Domer T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus ery-thematosus (see comment) (erratum appears in Arthritis Res 'Ther. 2008;10(5):406). Arthritis Res Ther 2006;8(3):R74.
   Google Scholar
• Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Domer T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis. 2008;67(4):450–7.
   PubMed Web of Science ®Google Scholar
• Petri M, Hobbs K, Gordon C, Strand V, Wallace D, Kelley L, et al. Clinically meaningful improvements with epratuzumab (Anti-CD22 mAb targeting B-cells) in patients (Pts) with moderate/severe SLE flares: results from 2 Randomized Controlled Trials American College of Rheumatology National Meeting 2008; Abstract 1087.
   Google Scholar
• Munafo A, Priestley A, Nestorov I, Visich J, Rogge M. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol. 2007;63(7):647–56.
   Google Scholar
• Tak PP, 'Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58(1):61–72.
   Google Scholar
• Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immuno-globulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56(12):4142–50.
   Google Scholar
• Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA. 2005;102(42):15178–83.
   PubMed Web of Science ®Google Scholar
• Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748–55.
   PubMed Web of Science ®Google Scholar
• Badros A, Goloubeva O, Dalal J, Can I, Thompson J, Rapoport A, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007;110:1042–8.
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnor-malities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50(11):3580–90.
   PubMedGoogle Scholar
• Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56(9):3044–56.
   PubMedGoogle Scholar
• Roll P, Domer T, Tony H-P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58(6): 1566–75.
   Google Scholar
• Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P. Regen-eration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377–86.
   Google Scholar
• Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis (see comment). Arthritis Rheum. 2006;54(2):613–20.
   PubMed Web of Science ®Google Scholar
• Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. Journal Immunol. 2009;182(10):5982–93.
   PubMed Web of Science ®Google Scholar
• Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 2007;178(10):6092–9.
   PubMed Web of Science ®Google Scholar
• Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol. 2004;172(6):3422–7.
   Google Scholar
• Rieger A, Bar-Or A. B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators (comment). Nat Rev Immunol. 2008;8(6):486–7.
   PubMed Web of Science ®Google Scholar
• Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Impor-tance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174(2):817–26.
   PubMed Web of Science ®Google Scholar
• Genovese M, Kaine J, Lowenstein M, Del Giudice J, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheuma-toid arthritis. Arthritis Rheum. 2008;58: 2652–61.
   Google Scholar
• Cambridge G, Isenberg DA, Edwards JCW, Leandro MJ, Migone TS, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis. 2008;67(7):1011–6.
   PubMed Web of Science ®Google Scholar
• Agenes F, Rosado MM, Freitas AA. Independent homeostatic reg-ulation of B cell compartments. Eur JImmunol. 1997;27(7):1801–7.
   PubMedGoogle Scholar
• Agenes F, Freitas AA. Transfer of small resting B cells into immunodeficient hosts results in the selection of a self-renewing activated B cell population. J Exp Med. 1999;189(2):319–30.
   PubMed Web of Science ®Google Scholar
• Gaudin E, Rosado M, Agenes F, McLean A, Freitas AA. B-cell homeostasis, competition, resources, and positive selection by self-antigens. Immunol Rev. 2004;197:102–15.
   Google Scholar
• Cappione A, Pugh A, Anolik J, Sanz I. Lymphocytotoxic auto-antibodies in SLE target a CD45 glycoform preferentially expressed in naive B cells. Arthritis Rheum. 2001;44:S74.
   Google Scholar
• Lin Q, Dong C, Cooper MD. Impairment of T and B cell development by treatment with a type I interferon. J Exp Med. 1998;187(1):79–87.
   Google Scholar
• Barnard J, Palanichamy A, Bauer J, Koeuth T, Baechler E, Anolik J. Interferon activation in human SLE bone marrow inhibits b cell lymphopoiesis American College of Rheumatology National Meeting 2008; Abstract 464.
   Google Scholar
• Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner ECB, et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol. 2008;180(2):688–92.
   PubMed Web of Science ®Google Scholar
• Jacobi A, Huang W, Wang T, Freimuth W, Sanz I, Aranow C, et al. Effects of chronic selective baff blockade on human B cells in SLE American College of Rheumatology National Meeting 2008; Abstract 1080.
   Google Scholar
• Sabahi R, Owen T, Barnard J, Cushing E, Looney R, Sanz I, et al. Immunologic effects of BAFF antagonism in the treatment of human SLE American College of Rheumatology National Meeting 2007; Abstract 1424.
   Google Scholar
• Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature. 1997;388(6638):133–4.
   PubMedGoogle Scholar
• Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol. 2005;23:367–86.
   PubMed Web of Science ®Google Scholar
• Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol. 2003;171(4):1684–90.
   PubMed Web of Science ®Google Scholar
• Hofer T, Muehlinghaus G, Moser K, Yoshida T, E Mei H, Hebel K, et al. Adaptation of humoral memory. Immunol Rev. 2006;211:295–302.
   PubMed Web of Science ®Google Scholar
• Hoyer B, Moser K, Hauser A, Peddinghaus A, Voigt C, Eilat D, et al. Short-lived plasmablasts and long-lived plasma cells con-tribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med. 2004;199:1577.
   PubMed Web of Science ®Google Scholar
• Mei H, Yoshida T, Sime W, Hiepe F, Thiele K, Manz R, et al. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood. 2009;113:2461–9.
   PubMed Web of Science ®Google Scholar
• Illei G, Austin H, Crane M, Collins L, Gourley M, Yarboro C, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:246–57.
   Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Eng J Med. 2004;350:971–80.
   Google Scholar
• Gourley M, Austin H, Scott D, Yarboro C, Vaughan E, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med. 1996;125:549–57.
   PubMed Web of Science ®Google Scholar
• Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe prolifera-tive lupus nephritis treated with pulse immunosuppressive ther-apy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46(4):995–1002.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D' Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50(12):3934–40.
   Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, EdR Garrido Ed, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide (see comment). Arthritis Rheum. 2002;46(8):2121–31.
   Google Scholar
• Toubi E, Kessel A, Rosner I, Rozenbaum M, Lorber M, Paran D, et al. Quinacrine added to ongoing therapeutic regimens attenu-ates anticardiolipin antibody production in SLE. Lupus. 2003;12(4):297–301.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Hulot J-S, Hammoud HA, Aymard G, Cacoub P, et al. Low-blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus (see comment). Arthritis Rheum. 2006;54(10):3284–90.
   Google Scholar
• Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473–80.
   PubMedGoogle Scholar
• Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxy-chloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366–70.
   Google Scholar
• Banat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev. 2008;223:271–83.
   PubMed Web of Science ®Google Scholar
• Huang W, Sinha J, Newman J, Reddy B, Budhai L, Furie R, et al. The effect of anti-CD40 ligand antibody on B cells in human sys-temic lupus erythematosus. Arthritis Rheum. 2002;46(6):1554–62.
   PubMed Web of Science ®Google Scholar